DBV Technologies | DBVT - Net Income


DBV Technologies reported $-33.16M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
Acadia Pharmaceuticals USD 3.64M 269.93M Mar/2026
Alnylam Pharmaceuticals USD 205.99M 19.57M Mar/2026
Amarin USD -1.22M 6.51M Dec/2025
BioCryst Pharmaceuticals USD 245.84M 232.95M Dec/2025
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
DBV Technologies USD -33.16M 8.71M Sep/2025
Esperion Therapeutics USD 61.83M 93.16M Dec/2025
Galectin Therapeutics USD -12.37M 880K Jun/2024
Halozyme Therapeutics USD 150.05M 291.64M Mar/2026
Incyte USD 303.33M 4.05M Mar/2026
Insmed USD -163.56M 164.92M Mar/2026
Ionis Pharmaceuticals USD -93M 136M Mar/2026
Neurocrine Biosciences USD 197.9M 44.2M Mar/2026
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
United Therapeutics USD 274.9M 89.4M Mar/2026